clinical trial · NCT06482112
Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016)
Merck Sharp & Dohme LLC·phase2·completed·n = 124
Metabolic Dysfunction-Associated Steatotic Liver DiseaseNon-alcoholic Fatty Liver DiseaseNonalcoholic Fatty Liver DiseaseLiver DiseaseEfinopegdutide
brief summary
This study will evaluate the effect of efinopegdutide administration once every 2 weeks (Q2W) versus once weekly (Q1W) on mean relative reduction from baseline in liver fat content (LFC) after 28 weeks, as well as the safety and tolerability of the different regimens of efinopegdutide.
started
Jul 29, 2024
primary completion
Jun 27, 2025
completion
Jun 27, 2025
last updated
Jul 15, 2025
official title
A Phase 2a Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Different Dosing Regimens of Efinopegdutide (MK-6024) in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol